Precision Neuro-Oncology based on the Avatar Precision Medical System
|Prof Do-Hyun NamDept. of Neurosurgery,
Refactory Cancer Department
Samsung Medical Center
However, such approaches have limitations since most of refractory solid cancers have a multitude of genetic aberrations with profound molecular heterogeneity, and prediction of therapeutic response is based on indirect evidence from unrelated cancer cell lines. Sustainable clinical success in precision oncology is more likely to be achieved by an integrated approach consisting of genomics and the patient cell-based drug screening.
For implementation of this innovative platform of precision medicine, we focused on glioblastoma (GBM), one of the most lethal tumors in human. Here, we have established over 80 models of GBM-derived cell panel and have accumulated cancer genome data of the parental tumors with the <i>in vitro</i> sensitivities of 60 targeted cancer drugs under clinical and preclinical investigation.Existing efforts in personalized medicine to evaluate the potential efficacy of a treatment are largely focused on identifying genomic predictors of response